NICE Backs Betula Verrucosa for Birch Pollen Allergy
New Sublingual Immunotherapy Offers Hope for Birch Pollen Allergy Sufferers
Table of Contents
A new sublingual immunotherapy treatment, ITULAZAX (Verrucosa Betula), has been recommended by the National Institute for Health and Care Excellence (NICE) for individuals in England suffering from moderate-to-severe allergic rhinitis or conjunctivitis triggered by birch tree pollen. This groundbreaking therapy offers a long-term solution by modifying the immune system’s response, aiming to induce immune tolerance rather than just managing symptoms.
Targeting Persistent Allergy Symptoms
ITULAZAX is indicated for patients whose moderate-to-severe birch pollen allergy symptoms persist despite the use of conventional symptom-relieving medications. To be eligible for this treatment, individuals must also have a confirmed positive test for sensitization to a member of the birch homologous group.
Allergic rhinitis, commonly known as hay fever, affects the nasal passages, causing symptoms like sneezing, itching, and a runny nose. Allergic conjunctivitis,conversely,impacts the eyes,leading to redness,itching,and watering. Both conditions can significantly impact quality of life, and birch pollen is a common and potent allergen responsible for these reactions during its season.
NICE estimates that up to 27,000 peopel in England could benefit from this innovative treatment, which works by targeting the underlying cause of the allergy.
Long-Term Immune Tolerance: A Paradigm Shift in Allergy Treatment
unlike traditional pharmacotherapies that only alleviate symptoms, ITULAZAX, containing Verrucosa Betula pollen extract, aims to retrain the immune system. By gradually exposing the body to increasing doses of the allergen, the treatment seeks to build long-term immune tolerance. This means the immune system becomes less reactive to birch pollen, potentially leading to a significant reduction or even elimination of allergic symptoms in the long run.
Robust Evidence from Phase 3 Clinical trials
NICE’s advice is based on a comprehensive systematic literature review, which included five key publications. The moast compelling evidence emerged from a randomized phase 3 clinical trial conducted in 2019. This trial involved 634 participants, aged between 12 and 65 years, who experienced persistent, moderate-to-severe allergic rhinitis and conjunctivitis due to birch pollen.
Participants were randomly assigned to receive either daily ITULAZAX (Verrucosa Betula) sublingual immunotherapy or a placebo. The treatment duration ranged from 6.5 to 9.5 months. The results were highly encouraging: patients receiving ITULAZAX demonstrated a significant 37% reduction in average daily symptom scores and a notable 49% decrease in their daily medication usage compared to the placebo group.
Well-Tolerated with Manageable Side effects
The clinical trial data indicates that ITULAZAX is generally well-tolerated by patients. The majority of reported adverse effects were mild to moderate local reactions, primarily associated with the sublingual administration method.
ITULAZAX is available in a sublingual lyophilisate form, meaning it dissolves under the tongue. The recommended dosage is one tablet daily for both adults and children aged five years and older. For optimal efficacy, it is advised to commence treatment at least 16 weeks prior to the anticipated start of the birch pollen season.
While the precise number of healthcare appointments that could be avoided through the use of ITULAZAX remains to be fully quantified, NICE has concluded that the treatment represents good value for money within the healthcare system. The drug is priced at approximately £80.12 for a pack of 30 tablets, though actual costs may vary due to negotiated discounts in different healthcare settings. This new therapeutic option marks a significant advancement in the management of birch pollen allergies, offering a promising path towards sustained relief and improved quality of life for many.